Janus Henderson Global Life Sciences Fund Class N JFNNX

Medalist Rating as of | See Janus Henderson Investment Hub
  • NAV / 1-Day Return 86.74  /  −1.51 %
  • Total Assets 5.8B
  • Adj. Expense Ratio
    0.680%
  • Expense Ratio 0.680%
  • Distribution Fee Level Below Average
  • Share Class Type Institutional
  • Category Health
  • Investment Style Large Blend
  • Min. Initial Investment 1M
  • Status Open
  • TTM Yield 0.48%
  • Turnover 30%

USD | NAV as of Jul 21, 2026 | 1-Day Return as of Jul 21, 2026, 12:11 AM GMT+0

Morningstar’s Analysis JFNNX

Will JFNNX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

One of our high-conviction healthcare offerings.

Senior Analyst Ramanand Kothari

Ramanand Kothari

Senior Analyst

Summary

Janus Henderson Global Life Sciences benefits from an exceptional lead manager, strong support resources, and a consistently applied robust investment process with prudent risk management, underpinning its Above Average People and Process Pillar ratings.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings JFNNX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 41.4
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

8.86 467M
Healthcare

Johnson & Johnson

6.92 364M
Healthcare

AstraZeneca PLC

4.39 231M
Healthcare

UnitedHealth Group Inc

4.30 227M
Healthcare

AbbVie Inc

3.92 207M
Healthcare

Revolution Medicines Inc Ordinary Shares

2.96 156M
Healthcare

Novartis AG ADR

2.71 143M
Healthcare

argenx SE ADR

2.51 132M
Healthcare

Thermo Fisher Scientific Inc

2.42 127M
Healthcare

Praxis Precision Medicines Inc Ordinary Shares

2.35 124M
Healthcare

Sponsor Center